

Anatara Animal Health Update

MELBOURNE, 18 November 2020: Anatara Lifesciences (ASX: ANR) is pleased to provide an update on challenge trials of select Anatara animal health assets.

The University of New England's Poultry Hub Australia has commenced the previously announced study "Efficacy of ANR-pf on the performance of broilers subject to subclinical and necrotic enteritis challenges".

Anatara has entered into an agreement to initiate a challenge study in weaner piglets with its recently developed bromelain-based formulation (BONIFF).

Anatara and Ridley Corporation Ltd (Ridley) have jointly entered into agreements with the Australasian Pork Research Institute Ltd (APRIL) and Murdoch University. APRIL will be providing grant funding for the challenge study "BONIFF-SMEC: An in-field practical delivery mechanism for improved weaner piglet performance". This study is to be conducted by Murdoch University with anticipated target completion of mid-2021.

This project aims to test a modified formulation of BONIFF in Semi-Moist Extruded Creep (SMEC) feed on weaning piglets under an enterotoxigenic *Escherichia coli* (ETEC) challenge model. The project seeks to determine the efficacy of this combined formulation on piglet health, welfare, and performance after weaning.

CEO Steve Lydeamore commented, "Anatara thanks APRIL for supporting this collaboration which combines Anatara and Ridley technologies together with Murdoch University's trial capabilities. Our objectives are aligned – to address piglet scours (diarrhoea) which is estimated to cost the Australian pig industry more than \$7 million each year".¹

¹ <https://www.business.qld.gov.au/industries/farms-fishing-forestry/agriculture/livestock/animal-welfare/pests-diseases-disorders/piglet-scours>

For more information please contact:

General inquiries	
Steven Lydeamore CEO, Anataara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anataara.com	Sue MacLeman Chair, Anataara Lifesciences Ltd +61 (0) 437 211 200 smacleman@anataara.com

About Anataara Lifesciences Ltd

Anataara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anataara is a life sciences company with expertise in developing products for animal and human health. Anataara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anataara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anataara Lifesciences Limited
Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

343 Royal Parade, Parkville, Melbourne, VIC 3052, Australia

Email info@anataara.com | Website anataaralifesciences.com

